Role of tyrosine phosphorylation in ligand-induced regulation of transcytosis of the polymeric Ig receptor.
The polymeric Ig receptor (pIgR) transcytoses its ligand, dimeric IgA (dIgA), from the basolateral to the apical surface of epithelial cells. Although the pIgR is constitutively transcytosed in the absence of ligand, binding of dIgA stimulates transcytosis of the pIgR. We recently reported that dIgA binding to the pIgR induces translocation of protein kinase C, production of inositol triphosphate, and elevation of intracellular free calcium. We now report that dIgA binding causes rapid, transient tyrosine phosphorylation of several proteins, including phosphatidyl inositol-specific phospholipase C-gammal. Protein tyrosine kinase inhibitors or deletion of the last 30 amino acids of pIgR cytoplasmic tail prevents IgA-stimulated protein tyrosine kinase activation, tyrosine phosphorylation of phospholipase C-gammal, production of inositol triphosphate, and the stimulation of transcytosis by dIgA. Analysis of pIgR deletion mutants reveals that the same discrete portion of the cytoplasmic domain, residues 727-736 (but not the Tyr734), controls both the ability of pIgR to cause dIgA-induced tyrosine phosphorylation of the phospholipase C-gammal and to undergo dIgA-stimulated transcytosis. In addition, dIgA transcytosis can be strongly stimulated by mimicking phospholipase C-gammal activation. In combination with our previous results, we conclude that the protein tyrosine kinase(s) and phospholipase C-gammal that are activated upon dIgA binding to the pIgR control dIgA-stimulated pIgR transcytosis.
Luton
F
F
Departments of Anatomy and Biochemistry, and Cardiovascular Research Institute, University of California, San Francisco, California 94143-0452, USA.
Cardone
M H
MH
Zhang
M
M
Mostov
K E
KE
D000818:Animals; D001692:Biological Transport; D002460:Cell Line; D003593:Cytoplasm / Q000201:enzymology / Q000502:physiology; D019281:Dimerization; D004285:Dogs; D004705:Endocytosis / Q000187:drug effects; D004789:Enzyme Activation / Q000187:drug effects; D019833:Genistein / Q000494:pharmacology; D007070:Immunoglobulin A / Q000378:metabolism / Q000502:physiology; D007295:Inositol Phosphates / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D007527:Isoenzymes / Q000378:metabolism; D007668:Kidney / Q000166:cytology; D008024:Ligands; D010446:Peptide Fragments / Q000502:physiology; D051966:Phospholipase C gamma; D010766:Phosphorylation; D011485:Protein Binding / Q000187:drug effects; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D019056:Receptors, Polymeric Immunoglobulin / Q000235:genetics / Q000378:metabolism*; D017384:Sequence Deletion; D010738:Type C Phospholipases / Q000378:metabolism; D014443:Tyrosine / Q000378:metabolism*
D007070:Immunoglobulin A; D007295:Inositol Phosphates; D007527:Isoenzymes; D008024:Ligands; D010446:Peptide Fragments; D019056:Receptors, Polymeric Immunoglobulin; D014443:Tyrosine; D019833:Genistein; D011505:Protein-Tyrosine Kinases; D010738:Type C Phospholipases; D051966:Phospholipase C gamma